Develops first-in-class oncology immunotherapeutics (lead molecule RB101) that boost cytotoxic lymphocyte persistence, memory formation and tumor killing without systemic toxicity or exhaustion. Offers a bispecific antibody platform to target and redirect cytotoxic lymphocytes within the tumor microenvironment.